---

Anti-viral herbal phytoconstituents of tulsi (Ocimum sanctum) against Covid-19

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Yamini Shah*, Kavish Shah

Volume : 7, Issue : 2, Year : 2022

Article Page : 77-80

https://doi.org/10.18231/j.ijcaap.2022.014

Suggest article by email

Get Permission

Abstract

A novel corona virus originated from Wuhan, China in 2019. Millions of people were affected due to this virus outbreak and quarantined for almost 2 years resulting in great loss in millions of lives in the world. This also resulted in a great impact in economy and health sector globally. After the outbreak the development of cure against SARS-CoV-2 is in full motion, less efforts have been spent on the prevention of rapidly spreading respiratory infectious agents. At present there is no effective treatment that could mitigate SARS-CoV-2. Available clinical intervention for covid-19 is only limited to support. Due to dreadful situation caused by COVID-19, there is an immediate need to discover potent therapeutic agents and targeted deliveries which can inhibit COVID-19 entry, progression and spread in human beings. Comprehensive understanding on the life cycle of SARS-CoV-2viruses and their interaction with hosts is important in the fight against these viruses. Thus, there is an urgent need for effective treatment. Intensive research on synthetic, semi synthetic, herbal, ayurvedic, siddha and unani drugs is necessary for this cause. In this review we focus on literature investigated on herbal drugs which might help in inhibition of COVID-19 via inhibition of angiotensinogen converting enzyme (ACE) and RNA dependent RNA polymerase (RdRp) through computational studies using AutoDockVina followed by their formulation development.
 

Keywords: Covid-19, Cure, Indian herbs, Medicinal properties, Tulsi(Ocimum sanctum), Phytoconstituents, Computational studies, Viral structure, Molecular docking

How to cite : Shah Y, Shah K, Anti-viral herbal phytoconstituents of tulsi (Ocimum sanctum) against Covid-19. IP Int J Compr Adv Pharmacol 2022;7(2):77-80

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.